Abstract Selectivity of 96 semisynthetic derivatives prepared from fungal pyripyropene A, originally isolated as a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), toward ACAT1 and ACAT2 isozymes was investigated in the cell-based assay using ACAT1-and ACAT2-expressing CHO cells. Eighteen derivatives including PR-71 (7-O-isocaproyl derivative) showed much more potent ACAT2 inhibition (IC 50 : 6.0 to 62 nM) than pyripyropene A (IC 50 : 70 nM). Among them, however, natural pyripyropene A showed the highest selectivity toward ACAT2 with a selectivity index (SI) of Ͼ1000, followed by PR-71 (SI, 667).
Introduction
Acyl-CoA:cholesterol acyltransferase (ACAT) plays important roles in cholesterol metabolism in mammals. Therefore, a large number of synthetic ACAT inhibitors such as ureas, imidazoles and amides have been reported [1] . However, pharmaceutical companies have so far failed to develop them as new types of cholesterol-lowering or anti-atherosclerotic agents [2] . Recently, the development of avasimibe [3] and pactimibe [4] has also failed.
Our research group started screening for ACAT inhibitors of natural origin with a chemical structure different from synthetic ones from the 1990s, and discovered a number of compounds [5] . Among them, pyripyropenes, fungal metabolites, were one of the most potent ACAT inhibitors in an enzyme assay using rat liver microsomes [6ϳ8] . Accordingly, about 200 derivatives were semisynthetically prepared from pyripyropene A. Certain derivatives were shown to be more potent than pyripyropene A, and proved to be active in reducing cholesterol absorption in vivo from the intestines of hamsters [9ϳ14] .
Recent molecular biological studies revealed the presence of two isozymes, ACAT1 and ACAT2 [15ϳ18]. ACAT1 is ubiquitously expressed, and high-level expression is observed in sebaceous glands, steroidogenic tissues, and macrophages, while ACAT2 is expressed predominantly in the liver and intestine [19] . In spite of this recent knowledge about ACAT isozymes, the selectivity of the inhibitors, even synthetic ones, toward the isozymes has not been fully studied. We established a cell-based assay using ACAT1-or ACAT2-expressing CHO cells and studied the selectivity of microbial ACAT inhibitors we have discovered toward the isozymes [20, 21] . We confirmed that pyripyropenes showed a very unique characteristics, namely ACAT2-selective inhibition.
In this study, 96 pyripyropene derivatives now available were evaluated in this cell-based assay to investigate their selectivie inhibition toward the ACAT isozymes.
Materials and Methods

Materials
Pyripyropene A was purified from the culture broth of the producing microorganism, Aspergillus fumigatus FO-1289, according to the established methods [6ϳ8] . [1- 14 C]oleic acid was purchased from PerkinElmer Life and Analytical Sciences (USA). Fetal bovine serum (FBS) was from HyClone (USA). HAM's F12 was obtained from Sigma-Aldrich (USA). Geneticin (G-418 sulfate) and MEM vitamin solution were from Wako Pure Chemical Industries (Japan). Penicillin (10,000 units/ml)/ streptomycin (10,000 mg/m) solution was from Invitrogen (USA). Plastic microplates (48-well) were purchased from Asahi Techno Glass (Japan). Ninety-six semisynthetic derivatives were prepared from pyripyropene A as reported previously [9ϳ14]. Among them, the structures of pyripyropene A and 35 derivatives are summarized in Fig. 1 and Table 1 .
Culture of ACAT1-and ACAT2-CHO Cells
Two cell lines, CHO cells expressing African Green monkey ACAT1 (ACAT1-CHO) and ACAT2 (ACAT2-CHO) [20] , were maintained at 37°C in 5.0% CO 2 in Ham's F-12 medium supplemented with MEM vitamins, geneticin (300 m g/ml) and 10% heat inactivated FBS (hereafter referred to as medium A). ]oleic acid in ACAT1-or ACAT2-CHO cells was carried out by our established method [21] . ACAT1-or ACAT2-CHO cells (1.25ϫ10 5 cells in 250 ml of medium A) were cultured in a 48-well plastic microplate and allowed to recover overnight at 37°C in 5.0% CO 2 . The assay was done with cells that were at least 80% confluent. Following overnight recovery, a test sample (2.5 ml in MeOH) and [1- buffered saline (PBS) solution) were added to each culture. After a 6-hour incubation at 37°C in 5.0% CO 2 , the medium was removed, and the cells in each well were washed twice with PBS. The cells were lysed by adding 0.25 ml of 10 mM Tris-HCl (pH 7.5) containing 0.1% (w/v) sodium dodecyl sulfate (SDS), and the cellular lipids were extracted by the method of Bligh and Dyer [22] . After the organic phase was concentrated, the total lipids were separated on a thin layer chromatography (TLC) plate (silica gel F254, 0.5 mm thick, Merck, Germany) and 
Results
All the semisynthetic pyripyropene derivatives (96 compounds) were tested in the cell-based assay using ACAT1-and ACAT2-CHO cells. Among them, 57 derivatives showed inhibitory activity against ACAT1 and/or ACAT2.
First, the IC 50 values of the derivatives against ACAT2 in the assay using ACAT2-CHO cells and against ACAT in the rat liver microsomes previously reported [9ϳ14] are plotted in Fig. 2 . A good correlation was obtained (Pearson rϭ0.867, PϽ0.001) between the two IC 50 values. The result is reasonable because rat livers specifically express ACAT2 isozymes [19] .
Next, the IC 50 values of these 57 derivatives against ACAT1 and ACAT2 activities are plotted in Fig. 3 . Among them, 27 derivatives showed ACAT2 selective inhibition with selectivity indexes (SI) of Ͼ10, 30 derivatives inhibited both isozymes (SI, Ͻ10), and no derivatives showed ACAT1 selective inhibition. These data indicate that the structural skeleton of pyripyropene fundamentally prefers the ACAT2 isozyme. Furthermore, 35 derivatives strongly inhibited with nano molar levels of IC 50 values. The structures and the IC 50 values are summarized in Fig. 1 and Table 1 . Eighteen of the 35 derivatives showed more potent ACAT2 inhibition than pyripyropene A in the cellbased assay, and 10 derivatives (PR-71, 72, 218, 60, 109, 118, 221, 171, 165 and 222) were more potent in both cellbased and microsomal assays. PR-171 was the most potent in the microsomal assay, and PR-71 was the most potent in the cell-based assay.
To assess the selectivity toward ACAT2 isozyme, the 35 derivatives were ordered according to their SIs (Table 1) . Among 27 derivatives having SIs of Ͼ10 as described, 9 derivatives (PR-71, 72, 220, 218, 60, 109, 156, 118, 221) were highly selective toward ACAT2 with SIs of Ͼ100. Surprisingly, pyripyropene A was the most selective in ACAT2 inhibition (SI, Ͼ1000), followed by PR-71 (SI, 667). CL-283, 546, a synthetic urea inhibitor, inhibited both ACAT1 and ACAT2, and beauveriolides I and III showed ACAT1 selective inhibition in the cell-based assay (Fig. 3) .
Discussion
The relationships between the structures of pyripyropene derivatives and their ACAT2 inhibitory activity in the cellbased assay were confirmed: 1) O-Acyl groups at the 1-, 11-and 7-positions are essential for inhibitory activity, 2) a free hydroxyl group at the 13-position is essential for the activity, and 3) the position of the nitrogen atom in the pyridine residue at the 6Ј-position is essential for the activity. These conclusions are comparative to those obtained in the rat liver mirosomal assay [9ϳ14] .
We have tested a number of ACAT inhibitors toward the ACAT1 and ACAT2 isozymes. Most of them were characterized into two groups; the first one includes CL-283, 546 [21] , avasimibe [3] and pactimibe [4] showing inhibition of both isozymes and the second one includes beauveriolides [21] and Wu-V-23 [20] showing selective inhibition of ACAT1. As confirmed in this study, pyripyropene A and its derivatives (the third group) have very unique characteristics of selectively inhibiting the ACAT2 isozyme. Therefore, pyripyropenes are expected to be developed as a new type of anti-atherosclerotic agent.
